newsfilter
← Latest News
ACCESS Newswire·

Lexaria Begins DehydraTECH-CBD Epilepsy Research Program

Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; DehydraTECH-CBD test articles have been delivered to the laboratory ready to commence dosing. KELOWNA, BC / ACCESSWIRE / March